MA
SLNO

Montag & Associates’s Soleno Therapeutics SLNO Stock Holding History

Montag & Associates’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-9
Closed -$609 – 1139
2025
Q3 		$609 Buy
+9
New +$667 ﹤0.01% 1066

Other funds holding SLNO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Montag & Associates's SLNO Position: Q4 2025 in Review

Montag & Associates sold out of Soleno Therapeutics (SLNO) in Q4 2025, closing a stake of 9 shares — an estimated $609 sold.

Montag & Associates first reported a position in SLNO in Q3 2025 and held it in 1 quarter. The position peaked at $609 in Q3 2025. 248 funds tracked by Wall St. Rank hold SLNO as of Q4 2025.

  • Montag & Associates reported no remaining Soleno Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Montag & Associates sold 9 Soleno Therapeutics shares in Q4 2025, an estimated $609.
  • Montag & Associates first reported a position in Soleno Therapeutics in Q3 2025 and held it in 1 quarter.
  • Montag & Associates's Soleno Therapeutics position peaked at $609 in Q3 2025.
  • 248 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q4 2025.

Based on Montag & Associates's 13F filing for Q4 2025, filed 2 Feb 2026.